{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:20:42Z","timestamp":1773832842199,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03470-7","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:33:31Z","timestamp":1768822411000},"page":"1341-1355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FF\/UMEC\/VI and BUD\/GLY\/FORM in Patients with COPD Stepping Up from Dual Therapy Stratified by Exacerbations and Prior Dual Therapy: A Subgroup Analysis of a Comparative Effectiveness Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9642-1261","authenticated-orcid":false,"given":"Jadwiga A.","family":"Wedzicha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-5579","authenticated-orcid":false,"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Di Boscio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-2950","authenticated-orcid":false,"given":"Olivier","family":"Le Rouzic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurita","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7151-4311","authenticated-orcid":false,"given":"Rosirene","family":"Paczkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-9590","authenticated-orcid":false,"given":"Stephen","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-7673","authenticated-orcid":false,"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3646-7828","authenticated-orcid":false,"given":"David","family":"Mannino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"3470_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2026 report. 2026. https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/. Accessed 25 Nov 2025."},{"key":"3470_CR2","unstructured":"US Food and Drug Administration. BREZTRI AEROSPHERE\u2122 (budesonide, glycopyrrolate, and formoterol fumarate). Prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212122s000lbl.pdf. Accessed 25 Nov 2025."},{"key":"3470_CR3","unstructured":"US Food and Drug Administration. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol). Prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209482s018lbl.pdf. Accessed 25 Nov 2025."},{"key":"3470_CR4","unstructured":"European Medicines Agency. Trixeo Aerosphere. 2024. http:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/trixeo-aerosphere. Accessed 25 Nov 2025."},{"key":"3470_CR5","unstructured":"European Medicines Agency. Trelegy Ellipta. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trelegy-ellipta. Accessed 25 Nov 2025."},{"key":"3470_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080409","volume":"387","author":"WB Feldman","year":"2024","unstructured":"Feldman WB, Suissa S, Kesselheim AS, et al. Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. BMJ. 2024;387:e080409. https:\/\/doi.org\/10.1136\/bmj-2024-080409.","journal-title":"BMJ"},{"issue":"2","key":"3470_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s12325-024-03088-1","volume":"42","author":"D Mannino","year":"2025","unstructured":"Mannino D, Weng S, Germain G, et al. Comparative effectiveness of fluticasone furoate\/umeclidinium\/vilanterol and budesonide\/glycopyrrolate\/formoterol fumarate among US patients with chronic obstructive pulmonary disease. Adv Ther. 2025;42(2):1131\u201346. https:\/\/doi.org\/10.1007\/s12325-024-03088-1.","journal-title":"Adv Ther"},{"issue":"9","key":"3470_CR8","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1007\/s12325-025-03295-4","volume":"42","author":"JA Wedzicha","year":"2025","unstructured":"Wedzicha JA, Noorduyn SG, Di Boscio V, et al. Comparative effectiveness of FF\/UMEC\/VI and BUD\/GLY\/FORM in patients with COPD stepping up from dual therapy. Adv Ther. 2025;42(9):4432\u201346. https:\/\/doi.org\/10.1007\/s12325-025-03295-4.","journal-title":"Adv Ther"},{"key":"3470_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2147\/COPD.S302241","volume":"16","author":"DW Mapel","year":"2021","unstructured":"Mapel DW, Roberts MH, Sama S, et al. Development and validation of a healthcare utilization-based algorithm to identify acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1687\u201398. https:\/\/doi.org\/10.2147\/COPD.S302241.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"3470_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151357","volume":"11","author":"KJ Rothnie","year":"2016","unstructured":"Rothnie KJ, M\u00fcllerov\u00e1 H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS ONE. 2016;11(3):e0151357. https:\/\/doi.org\/10.1371\/journal.pone.0151357.","journal-title":"PLoS ONE"},{"issue":"1","key":"3470_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","volume":"23","author":"JR Hurst","year":"2022","unstructured":"Hurst JR, Han MK, Singh B, et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022;23(1):213. https:\/\/doi.org\/10.1186\/s12931-022-02123-5.","journal-title":"Respir Res"},{"key":"3470_CR12","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.2147\/COPD.S175047","volume":"13","author":"JL Izquierdo","year":"2018","unstructured":"Izquierdo JL, Cosio BG. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int J Chron Obstruct Pulmon Dis. 2018;13:3539\u201347. https:\/\/doi.org\/10.2147\/COPD.S175047.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3470_CR13","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple therapies versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1713901.","journal-title":"N Engl J Med"},{"key":"3470_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1916046.","journal-title":"N Engl J Med"},{"issue":"9","key":"3470_CR15","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s12325-019-01015-3","volume":"36","author":"F Maltais","year":"2019","unstructured":"Maltais F, Ferguson GT, Feldman GJ, et al. A randomized, double-blind, double-dummy study of glycopyrrolate\/formoterol fumarate metered dose inhaler relative to umeclidinium\/vilanterol dry powder inhaler in COPD. Adv Ther. 2019;36(9):2434\u201349. https:\/\/doi.org\/10.1007\/s12325-019-01015-3.","journal-title":"Adv Ther"},{"issue":"2","key":"3470_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s12325-024-03055-w","volume":"42","author":"C Young","year":"2025","unstructured":"Young C, Lee LY, DiRocco KK, et al. Adherence and persistence with single-inhaler triple therapy among patients with COPD using commercial and Medicare Advantage US health plan claims data. Adv Ther. 2025;42(2):830\u201348. https:\/\/doi.org\/10.1007\/s12325-024-03055-w.","journal-title":"Adv Ther"},{"key":"3470_CR17","unstructured":"Elixhauser A, Steiner C, Kruzikas D. HCUP comorbidity software. Healthcare Cost and Utilization Project (HCUP). Rockville: Agency for Healthcare Research and Quality; 2015. http:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp#download."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03470-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:30:12Z","timestamp":1773822612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03470-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3470"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03470-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jadwiga A. Wedzicha reports grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, and Novartis, consulting fees from AstraZeneca, EpiEndo Pharmaceuticals, GSK, Gilead, Novartis, Pfizer, Roche, and Empirico, honoraria for lectures, presentations or educational events from AstraZeneca, Boehringer Ingelheim, Glenmark, GSK, Novartis, Recipharm, Roche, and Sanofi, and participation as the data safety monitoring board chair for Virtus. Stephen G. Noorduyn, Valentina Di Boscio, Anurita Majumdar, Rosirene Paczkowski, and Stephen Weng are employees of GSK and\/or hold financial equities in GSK. Stephen G. Noorduyn is also a PhD candidate at McMaster University. Olivier Le Rouzic is a principal investigator of CSL Behring and Vertex studies and has received receiving personal fees and\/or congress support from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, LFB, and Sanofi outside the submitted work. Guillaume Germain and Fran\u00e7ois Lalibert\u00e9 are employees of Groupe d\u2019analyse which received funding from GSK to conduct this study but not for manuscript development. David Mannino is a consultant for AstraZeneca, the COPD Foundation, Genentech, GSK, Regeneron, and UpToDate. David Mannino is also an expert witness on behalf of people suing the tobacco and vaping industries.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study complied with all applicable laws regarding patient privacy, as described in the Declaration of Helsinki. No direct patient contact or primary collection of individual human patient data occurred in this study. This study used existing, fully de-identified data that complied with the requirements of the Health Insurance Portability and Accountability Act and the patient(s) cannot be identified, directly or through identifiers. Study results were in tabular form and aggregate analyses that omit patient identification; therefore, informed consent and ethics committee or institutional review board approval were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}